188 related articles for article (PubMed ID: 21150923)
21. Epidemiological features and prognostic factors of cutaneous head and neck melanoma: a population-based study.
Golger A; Young DS; Ghazarian D; Neligan PC
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):442-7. PubMed ID: 17515502
[TBL] [Abstract][Full Text] [Related]
22. Is sentinel lymph node biopsy of therapeutic relevance for melanoma?
Möhrle M; Schippert W; Rassner G; Garbe C; Breuninger H
Dermatology; 2004; 209(1):5-13. PubMed ID: 15237261
[TBL] [Abstract][Full Text] [Related]
23. The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival.
Baehner FL; Li R; Jenkins T; Hwang J; Kashani-Sabet M; Allen RE; Leong SP
Ann Surg Oncol; 2012 Mar; 19(3):1034-42. PubMed ID: 21989664
[TBL] [Abstract][Full Text] [Related]
24. Age and gender are significant independent predictors of survival in primary cutaneous melanoma.
Lasithiotakis K; Leiter U; Meier F; Eigentler T; Metzler G; Moehrle M; Breuninger H; Garbe C
Cancer; 2008 Apr; 112(8):1795-804. PubMed ID: 18306371
[TBL] [Abstract][Full Text] [Related]
25. Deep lymph node metastases in the groin significantly affects prognosis, particularly in sentinel node-positive melanoma patients.
Niebling MG; Wevers KP; Suurmeijer AJ; van Ginkel RJ; Hoekstra HJ
Ann Surg Oncol; 2015 Jan; 22(1):279-86. PubMed ID: 25008028
[TBL] [Abstract][Full Text] [Related]
26. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
Tas F; Keskin S; Karadeniz A; Dağoğlu N; Sen F; Kilic L; Yildiz I
Oncology; 2011; 81(5-6):353-8. PubMed ID: 22248874
[TBL] [Abstract][Full Text] [Related]
27. Value of anatomic site, histology and clinicopathological parameters for prediction of lymph node metastasis and overall survival in head and neck melanomas.
Ettl T; Irga S; Müller S; Rohrmeier C; Reichert TE; Schreml S; Gosau M
J Craniomaxillofac Surg; 2014 Jul; 42(5):e252-8. PubMed ID: 24216129
[TBL] [Abstract][Full Text] [Related]
28. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma.
Gipponi M; Solari N; Giovinazzo D; Queirolo P; Bertoglio S; Villa G; Gualco M; Bleidl D; Cafiero F
Anticancer Res; 2014 Jun; 34(6):3197-203. PubMed ID: 24922694
[TBL] [Abstract][Full Text] [Related]
29. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Mozzillo N; Pasquali S; Santinami M; Testori A; Di Marzo M; Crispo A; Patuzzo R; Verrecchia F; Botti G; Montella M; Rossi CR; Caracò C
Eur J Surg Oncol; 2015 Jul; 41(7):823-9. PubMed ID: 25800935
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
31. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients.
Karakousis GC; Gimotty PA; Czerniecki BJ; Elder DE; Elenitsas R; Ming ME; Fraker DL; Guerry D; Spitz FR
Ann Surg Oncol; 2007 May; 14(5):1596-603. PubMed ID: 17285396
[TBL] [Abstract][Full Text] [Related]
32. Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.
Calomarde-Rees L; García-Calatayud R; Requena Caballero C; Manrique-Silva E; Traves V; García-Casado Z; Soriano V; Kumar R; Nagore E
JAMA Dermatol; 2019 Jun; 155(6):679-687. PubMed ID: 31042264
[TBL] [Abstract][Full Text] [Related]
33. Sex differences in melanoma survival are not related to mitotic rate of the primary tumor.
Joosse A; van der Ploeg AP; Haydu LE; Nijsten TE; de Vries E; Scolyer RA; Eggermont AM; Coebergh JW; Thompson JF
Ann Surg Oncol; 2015 May; 22(5):1598-603. PubMed ID: 25408275
[TBL] [Abstract][Full Text] [Related]
34. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
35. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features.
Elder DE; Gimotty PA; Guerry D
Dermatol Ther; 2005; 18(5):369-85. PubMed ID: 16297012
[TBL] [Abstract][Full Text] [Related]
37. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
38. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
39. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors in young women with cutaneous melanoma.
Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
